Head-To-Head Analysis: Sentage (NASDAQ:SNTG) vs. Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and Sentage (NASDAQ:SNTG) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares Hyperion DeFi and Sentage”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	59.28	-$45.31 million	($6.53)	-0.47
Sentage	$70,000.00	68.24	-$2.28 million	N/A	N/A

Sentage has lower revenue, but higher earnings than Hyperion DeFi.

Analyst Recommendations

This is a summary of recent recommendations for Hyperion DeFi and Sentage, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	2	0	2.00
Sentage	1	0	0	0	1.00

Hyperion DeFi presently has a consensus target price of $7.20, indicating a potential upside of 133.01%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, research analysts clearly believe Hyperion DeFi is more favorable than Sentage.

Risk and Volatility

Hyperion DeFi has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Comparatively, Sentage has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Profitability

This table compares Hyperion DeFi and Sentage’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	416.56%	-11.62%	-9.96%
Sentage	N/A	N/A	N/A

Institutional and Insider Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 0.1% of Sentage shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 62.4% of Sentage shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Hyperion DeFi beats Sentage on 7 of the 12 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Sentage

Sentage Holdings Inc. provides a range of financial services. The company offers consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. It also provides consultancy and information technology support services. Sentage Holdings Inc. was incorporated in 2019 and is headquartered in Shanghai, the People's Republic of China.